Advertisement|Remove ads.

Shares of Unichem Laboratories fell 2.8% on Friday after the company said it received a demand notice from the European Commission, Brussels, for payment of a fine of 19.49 million euros in the Perindopril drug matter.
The amount includes a principal penalty of 13.97 million euros and interest of 5.52 million euros.
The company said its wholly owned subsidiary has already remitted 2.79 million euros in installments, leaving a balance of 16.70 million euros payable. Unichem noted it had already provided for the principal amount in its books, but the interest liability will now be recorded in FY25–FY26.
Advertisement|Remove ads.
The case stems from allegations that Unichem and its subsidiary, Niche Generics Ltd, breached European Union competition law by settling a Perindopril patent dispute with Servier Group in 2005.
The company said it is evaluating legal options in consultation with its law firm.
Technical View
Advertisement|Remove ads.
SEBI-registered analyst Sunil Kotak said the stock is currently in consolidation phase. Kotak said the stock looks supported around ₹475–₹480, but could run into selling pressure near ₹515–₹520.
He noted that a key momentum indicator has turned weak, and warned that a close below ₹475 might drag the stock lower.
Advertisement|Remove ads.
What Is The Retail Mood?
On Stocktwits, retail sentiment was ‘bearish’ amid ‘normal’ message volume.
Unichem Laboratories’ stock has declined 33% so far in 2025.
Advertisement|Remove ads.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Comments posted here will also appear on symbol pages.